This site is intended for healthcare professionals

Myovant Sciences and Pfizer announce positive one-year data from phase III SPIRIT extension study of once-daily relugolix combination therapy in women with endometriosis.

Read time: 1 mins
Last updated:27th Jan 2021
Published:27th Jan 2021
Condition: Pain; Endometriosis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest